Company Analysis
Sign in

Fulcrum Therapeutics, Inc. (FULC)

Nasdaq: FULC · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.2
◀ Past 4.7● Present 6.2▶ Future 4.7
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Fulcrum Therapeutics, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
19
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry3
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Fulcrum Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
17 published
Fulcrum Therapeutics, Inc. its own name
US, as the owner printed on each patent
8 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 8, 202412,109,198Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsOrganic fine chemistryFulcrum Therapeutics, Inc.
Nov 21, 202311,819,554Compositions and methods for modulating FMR1 expressionPharmaceuticalsFulcrum Therapeutics, Inc.
Feb 28, 202311,590,111Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsOrganic fine chemistryFulcrum Therapeutics, Inc.
Oct 25, 202211,479,770Use of p38 inhibitors to reduce expression of DUX4PharmaceuticalsFulcrum Therapeutics, Inc.
Apr 5, 202211,291,659P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDPharmaceuticalsFulcrum Therapeutics, Inc.
Apr 13, 202110,973,805Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsOrganic fine chemistryFulcrum Therapeutics, Inc.
Jan 21, 202010,537,560P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDPharmaceuticalsFulcrum Therapeutics, Inc.
Jul 9, 201910,342,786P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHDPharmaceuticalsFulcrum Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 10, 20252025/0223560NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLEPharmaceuticalsFulcrum Therapeutics, Inc.
Jul 3, 20252025/0213543AN EMBRYONIC ECTODERM DEVELOPMENT INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASEPharmaceuticalsFulcrum Therapeutics, Inc.
Jun 19, 20252025/0195480MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORSOrganic fine chemistryFulcrum Therapeutics, Inc.
Nov 7, 20242024/0368185MACROCYCLIC AZOLOPYRIDINESOrganic fine chemistryFulcrum Therapeutics, Inc.
Oct 17, 20242024/0342148METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY WITH LOSMAPIMODMedical technologyFulcrum Therapeutics, Inc.
Jul 18, 20242024/0238296METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERSPharmaceuticalsFulcrum Therapeutics, Inc.
Jun 20, 20242024/0199645POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINEOrganic fine chemistryFulcrum Therapeutics, Inc.
May 2, 20242024/0139163MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORSOrganic fine chemistryFulcrum Therapeutics, Inc. · patent 12,109,198 granted from it
Aug 17, 20232023/0257743USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4PharmaceuticalsFulcrum Therapeutics, Inc.
Sep 8, 20222022/0282254P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHDPharmaceuticalsFulcrum Therapeutics, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 4 · Pharmaceuticals 3 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton FULC · research, not advice